FDA approves tedizolid phosphate for skin infections

Slideshow

Skin and Soft Tissue Infections
Staphylococcus aureus, a gram positive bacteria believed to be carried by approximately 30% to 50% of healthy individuals at any given time, is responsible for the majority of skin and soft tissue infections that primary care physicians treat.

FDA approves tedizolid phosphate for skin infections

HealthDay News — The FDA has approved the antibiotic tedizolid phosphate (Sivextro) to treat adult patients diagnosed with skin infections.

Tedizolid phosphate, which may be taken intravenously or orally as a pill, is designed to treat infections including methicillin-resistant Staphylococcus aureus (MRSA), the agency said in a news release.

To evaluate tedizolid phosphate’s safety and effectiveness, 1,315 patients with serious-to-severe skin infections were followed in two clinical trials. The most common side effects recorded were nausea, headache, diarrhea, vomiting and dizziness, reported the agency. The drug was not evaluated among adults with neutropenia.

Tedizolid phosphate is the second new antibiotic for skin infections approved by the FDA in the past month.

“[This] approval provides physicians and patients with a new treatment option for serious skin infections,” Edward Cox, MD, MPH, of the FDA said.

Topics:

Dermatology Drug Approvals Infection Control Infectious Disease

FDA approves tedizolid phosphate for skin infections

Slideshow

Topics:

Want to read more?

Prior hospitalizations may predict stroke readmission